Lori Kunkel

Lori has more than two decades of experience in oncology and immunology drug development and commercialization.

Lori currently serves on the Board of Directors of Curis, Inc., Nurix Therapeutics, ORIC Pharmaceuticals, and Maverick Therapeutics. She was previously the acting Chief Medical Officer at Loxo Oncology and subsequently served on their board. She also served as Chief Medical Officer at Pharmacyclics (acquired by AbbVie) and Proteolix, Inc. (acquired by Onyx Pharmaceuticals), where she contributed to the global approvals of cancer therapeutics Imbruvica® (ibrutinib) and Kyprolis® (carfilzomib), respectively. She participates as a scientific advisor to multiple clients including Atreca, Elevation Oncology, Jasper Therapeutics, Oncopeptides, Oryzon, and Rain Therapeutics.

Lori spent ten years in academic medicine and served as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at the University of California, Los Angeles.

She is board certified in internal medicine and held board certifications in hematology and oncology. She earned a Bachelor of Arts in Biology from the University of California, San Diego.